ERBB2 and breast cancer: Through ROCplot, we found that SFRP1 (202037_s_at) was correlated to pathological complete response in breast cancer regardless of any chemotherapy (taxane, anthracycline, ixabepilone, CMF (cyclophosphamide, methotrexate, and fluorouracil), FAC (fluorouracil, Adriamycin, and cytoxan), or FEC (fluorouracil, epirubicin, and cyclophosphamide)) (AUC = 0.578, P < 0.0001) (Supplementary Figure 7A), hormone therapy (tamoxifen or aromatase inhibitor) (AUC = 0.629, P = 0.048) (Supplementary Figure 7B), and anti-HER2 therapy (trastuzumab or lapatinib) (AUC = 0.566, P = 0.047) (Supplementary Figure 7C).